the term usually refers to threats made to competitors about a brand name manufacturer s tactical use of pharmaceutical patents including over uses delivery systems and even packaging not to extension of any particular patent over an active product ingredient the evergreening process has caused some controversy in the pharmaceutical industry in this context evergreening may be used by manufacturers of a particular drug to restrict or prevent competition from manufacturers of generic equivalents to that drug in 2002 an extensive and lengthy inquiry by the us federal trade commission ftc found that the hatch waxman legislation or drug price competition and patent term restoration act which was instrumental in establishing the us generic pharmaceuticals industry had resulted in as many as 75 of new drug applications by generic drug manufacturers experiencing legal actions under patent laws by the original brand name patent owner these were driving up us drug costs by keeping the cheaper generic versions off the market the ftc recommended only one evergreening injunction against a potential generic market entrant be permitted per product and an expedited process of resolving such claims the process of evergreening may involve specific aspects of patent law and international trade law